Literature DB >> 3365690

Increase in radioresponse of murine tumors by treatment with indomethacin.

Y Furuta1, N Hunter, T Barkley, E Hall, L Milas.   

Abstract

Indomethacin, an inhibitor of prostaglandin (PG) synthesis, was investigated for its ability to increase radioresponse of two fibrosarcomas, FSA and NFSA, in C3Hf/Kam mice. In addition, the effect of indomethacin on radioresponse of hematopoietic tissue, jejunum, hair follicles, and tissues involved in the development of radiation-induced leg contractures was determined. Indomethacin greatly increased radioresponse of 8-mm tumors, as assessed by both tumor growth delay and TCD50 assays. Enhancement factors for tumor growth delay and tumor radiocurability (TCD50) were 1.55 and 1.39, respectively, for FSA, and 1.4 and 1.26, respectively, for NFSA tumors. Of four normal tissues assessed, two (hair follicles and tissues responsible for development of leg contractures) showed no change in radioresponse after treatment with indomethacin, one (hematopoietic tissue) exhibited radioprotection, and one (jejunum) exhibited slight radiosensitization (enhancement factor, 1.12). Therefore, indomethacin significantly augmented tumor radiocurability but had minimal effect on radioresponse of some normal tissues.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3365690

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

Authors:  Leandro C A Cerchietti; Marcelo R Bonomi; Alfredo H Navigante; Monica A Castro; Maria E Cabalar; Berta M C Roth
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective Cox-2 inhibitor.

Authors:  Bhupesh Parashar; Sai Latha Shankar; Kathleen O'Guin; James Butler; Bhadrasain Vikram; Bridget Shafit-Zagardo
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

3.  Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells.

Authors:  Irene V Bijnsdorp; Jaap van den Berg; Gitta K Kuipers; Laurine E Wedekind; Ben J Slotman; Johannes van Rijn; M Vincent M Lafleur; Peter Sminia
Journal:  J Neurooncol       Date:  2007-04-20       Impact factor: 4.130

4.  Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.

Authors:  B A Teicher; T T Korbut; K Menon; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 5.  Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?

Authors:  Zhongxing Liao; Kathryn A Mason; Luka Milas
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature.

Authors:  Michiel Wagemakers; Gesiena E van der Wal; Rosa Cuberes; Inés Alvarez; Eva Ma Andrés; Jordi Buxens; José M Vela; Henk Moorlag; Jan Jakob A Mooij; Grietje Molema
Journal:  Transl Oncol       Date:  2009-03       Impact factor: 4.243

7.  Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response.

Authors:  Pei-Ming Chu; Shih-Hwa Chiou; Tsann-Long Su; Yi-Jang Lee; Li-Hsin Chen; Yi-Wei Chen; Sang-Hue Yen; Ming-Teh Chen; Ming-Hsiung Chen; Yang-Hsin Shih; Pang-Hsien Tu; Hsin-I Ma
Journal:  Radiat Oncol       Date:  2011-01-19       Impact factor: 3.481

Review 8.  Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation.

Authors:  Giovanni L Gravina; Claudio Festuccia; Francesco Marampon; Vladimir M Popov; Richard G Pestell; Bianca M Zani; Vincenzo Tombolini
Journal:  Mol Cancer       Date:  2010-11-25       Impact factor: 27.401

9.  Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model.

Authors:  Takeshi Inoue; Satoshi Anai; Sayuri Onishi; Makito Miyake; Nobumichi Tanaka; Akihide Hirayama; Kiyohide Fujimoto; Yoshihiko Hirao
Journal:  BMC Urol       Date:  2013-01-05       Impact factor: 2.264

10.  Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations.

Authors:  S R Li; Q Yang; E Wandl; W Pirker; I Virgolini
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.